Doctor’s Guide -- SAN DIEGO -- October 10, 2010 -- Adding the novel glucagon-like peptide-1 analogue taspoglutide to metformin with or without thiazolidinedione elicited beneficial changes in body weight, waist and hip circumferences, and satiety in patients with type 2 diabetes. However, these changes were similar to those resulting from exenatide treatment, according to a presentation here at Obesity 2010: 28th Annual Scientific Meeting of The Obesity Society.
